Pharmaceutical Characterization of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Vaccine Used for the Treatment of Superficial Bladder Cancer
- 1 June 1993
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 82 (6) , 555-562
- https://doi.org/10.1002/jps.2600820602
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity?Urological Research, 1992
- High-dose inhibition and low-dose enhancement of murine sarcoma growth exhibited by BCG vaccineCancer Letters, 1991
- Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancerUrological Research, 1991
- This Month in Investigative Urology: The Production of Lymphokines Following BCG TherapyJournal of Urology, 1990
- Radio-Immunoassay Detection of Interferon-Gamma in Urine after Intravesical Evans BCG TherapyJournal of Urology, 1990
- Elevations of Cytokines Interleukin-1, Interleukin-2 and Tumor Necrosis Factor in the Urine of Patients after Intravesical Bacillus Calmette-Guerin ImmunotherapyJournal of Urology, 1990
- BCG Immunotherapy in Bladder Cancer: A ReassessmentPublished by American Medical Association (AMA) ,1988
- Bacillus Calmette-Guerin Immunotherapy for Bladder CancerJournal of Urology, 1985
- BCG as Adjuvant Immunotherapy for NeoplasiaAnnual Review of Medicine, 1977
- BCG Vaccine and Its DerivativesPublished by American Medical Association (AMA) ,1976